Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 816

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 816
---
 with a third party, according to which the third party would perform research for the Company for three years in accordance with a predetermined research plan in exchange for a payment of USD $480 thousand. In addition, a third party granted the Company a license to use the technology it had developed in exchange for royalties equal to 5% of product sales and the provision of drug scanning services for a period of 15 years from the date the Company’s sales commence, as well as 20% of the proceeds from the sale of sub -licensesby the Company. In case the Company is obligated to pay royalties to another party in connection with the same product, the aforementioned royalty rate shall be reduced to 3.5% and 15%, respectively. In May 2013, the Company signed an amendment to the agreement. According to the amendment, the third party would perform research for the Company for another four years in accordance with a predetermined research plan in exchange for a payment of USD $480 thousand. In addition, the Company would pay royalties equal to 5% of the Company’s revenues from product sales and the provision of drug scanning services, and 20% of the proceeds from the sale of sublicenses by the Company, as well as royalties at rates ranging from 2% to 7.5% for the sale of drug scanning products and additional receipts that the Company would receive from these products. In case the Company is obligated to pay royalties to another party in connection with the same product, the aforementioned royalty rate shall be reduced to 3.5%, 15%, and a rate ranging from 1.4% to 5.25%, respectively. On January 19, 2016, the Company entered into an addendum to the agreement with the third party, under which the Company would receive a non -exclusivelicense to use stem cells for the production of a cell therapy for ALS. The license also included scientific research to be carried out in third -partyresearch laboratories.

Annex G-30 KADIMASTEM LTD.
NOTES TO FINANCIAL STATEMENTS Note 17: — Contingent liabilities and COMMITMENTS (cont.) On March 24, 2020, the Company entered into an addendum to the agreement with the third party under which all the Company’s contracts became a non -exclusivelicense to use stem cells to create a cell therapy. In return, the rate of all royalties was reduced to 4% (compared to 5%) of product sales for a